Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

Wang,Hui‑Li; Liu,Yan‑Chun; Long,Ming‑Peng; Zheng,Chuan; Yang,Jia‑Hui

doi:10.3892/ol.2019.10643

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

Authors:
- Hui‑Li Wang
- Yan‑Chun Liu
- Ming‑Peng Long
- Chuan Zheng
- Jia‑Hui Yang
View Affiliations

Affiliations: School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China, State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, P.R. China
Published online on: July 22, 2019 https://doi.org/10.3892/ol.2019.10643
Pages: 2977-2984
Copyright : © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported that receptor tyrosine kinase‑like orphan receptor 1 (ROR1) acts as a hepatocyte growth factor receptor (MET) and c‑Src substrate, and that the extracellular domain of ROR1 is associated with EGFR to sustain EGFR‑ERBB3‑PI3K signaling. Our previous study reported that blocking ROR1 significantly decreased the activity of key signal molecules in the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which was associated with a significant increase of apoptosis and significant decrease of proliferation of lung adenocarcinoma cells. The present study hypothesized that inhibiting ROR1 could potentially prevent erlotinib resistance in NSCLC cell lines. Investigations were performed with two erlotinib‑resistant cell lines XLA‑07 and NCI‑H1975, and an erlotinib‑acquired‑resistant cell line PC‑9erlo, which was developed from its parental cell line PC‑9. It was identified that the inhibition of ROR1 via small interfering RNA treatment significantly improved the anti‑proliferation and apoptosis‑inducing roles of erlotinib in TKI‑resistant tumor cells. This was in accordance with the activity of key molecules of the AKT/mTOR signaling pathway, including glycogen synthase kinase‑3α/β (GSK‑3α/β), phosphatase and tensin homolog (PTEN), AKT, mTOR and ribosomal protein S6 kinase β‑1 (p70S6K). The current data suggest that targeting ROR1 is a potential novel treatment strategy for patients with ROR1‑positive NSCLC, particularly those with acquired resistance to EGFR‑TKI.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
3	Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr K and Peters S; ESMO Guidelines Working Group, : Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nascimento A, Bousbaa H, Ferreira D and Sarmento B: Non-small cell lung carcinoma: An overview on targeted therapy. Curr Drug Targets. 16:1448–1463. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI
6	Gadgeel SM and Wozniak A: Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer. 14:322–332. 2013. View Article : Google Scholar : PubMed/NCBI
7	Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YL, Choo JR, Goh BC and Soo RA: Third generation EGFR TKIs: Current data and future directions. Mol Cancer. 17:292018. View Article : Google Scholar : PubMed/NCBI
8	Wu SG and Shih JY: Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
9	Lin Y, Wang X and Jin H: EGFR-TKI resistance in NSCLC patients: Mechanisms and strategies. Am J Cancer Res. 4:411–435. 2014.PubMed/NCBI
10	Morgillo F, Della Corte CM, Fasano M and Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
11	Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, et al: Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 28:2451–2457. 2017. View Article : Google Scholar : PubMed/NCBI
12	Heydt C, Michels S, Thress KS, Bergner S, Wolf J and Buettner R: Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. Oncotarget. 9:15418–15434. 2018. View Article : Google Scholar : PubMed/NCBI
13	Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu K: EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
14	Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29:i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
15	Laurila N and Koivunen JP: EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. Med Oncol. 32:2052015. View Article : Google Scholar : PubMed/NCBI
16	Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, et al: Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 5:960–971. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, et al: Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget. 8:53068–53083. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang S, Ju D, Ye L and Feng M: Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci Rep. 7:45592017. View Article : Google Scholar : PubMed/NCBI
19	Tang X, Yan L, Zhu L, Jiao D, Chen J and Chen Q: Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt-mTOR pathway. J Pharmacol Sci. 135:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ye M, Wang S, Wan T, Jiang R, Qiu Y, Pei L, Pang N, Huang Y, Huang Y, Zhang Z and Yang L: Combined inhibitions of glycolysis and AKT/autophagy can overcome resistance to EGFR-targeted therapy of lung cancer. J Cancer. 8:3774–3784. 2017. View Article : Google Scholar : PubMed/NCBI
21	Fu Y, Li C, Luo Y, Li L, Liu J and Gui R: Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a. Front Pharmacol. 9:822018. View Article : Google Scholar : PubMed/NCBI
22	Ni J, Zhou LL, Ding L, Zhang XQ, Zhao X, Li H, Cao H, Liu S, Wang Z, Ma R, et al: Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells. Cancer Med. 7:1955–1966. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Dong X, Ren Y, Luo J, Liu P, Su D and Yang X: Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 9:1292018. View Article : Google Scholar : PubMed/NCBI
24	Wang YC, Wu DW, Wu TC, Wang L, Chen CY and Lee H: Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression. Int J Biol Sci. 14:47–56. 2018. View Article : Google Scholar : PubMed/NCBI
25	Masiakowski P and Carroll RD: A novel family of cell surface receptor with tyrosine kinase-like domain. J Biol Chem. 267:26181–26190. 1992.PubMed/NCBI
26	Borcherding N, Kusner D, Liu GH and Zhang W: ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 5:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y and Yang J: Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma. PLoS One. 10:e01270922015. View Article : Google Scholar : PubMed/NCBI
28	Gentile A, Lazzari L, Benvenuti S, Trusolino L and Comoglio P: The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer. 135:2305–2316. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H and Takahashi T: NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 21:348–361. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ma LJ, Wang HZ, Bian L, Shao WP, Tang RZ, Wang QQ and Jin KW: Establishment and characterization of lung adenocarcinoma cell line XLA-07. Zhonghua Bing Li Xue Za Zhi. 41:335–339. 2012.(In Chinese). PubMed/NCBI
31	Zhao YM, Su B, Yang XJ, Shi JY, Tang L, Zhang J, Li JY and Chen J: Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines. Zhonghua Zhong Liu Za Zhi. 35:103–108. 2013.(In Chinese). PubMed/NCBI
32	Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A and Rader C: Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One. 6:e210182011. View Article : Google Scholar : PubMed/NCBI
33	Yang T, Zhang Y, Li Y, Hao Y, Zhou M, Dong N and Duan X: High amounts of fluoride induce apoptosis/cell death in matured ameloblast-like LS8 cells by downregulating Bcl-2. Arch Oral Biol. 58:1165–1173. 2013. View Article : Google Scholar : PubMed/NCBI
34	Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, et al: Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 19:637–648. 2017. View Article : Google Scholar : PubMed/NCBI
35	Liu J, Xing Y and Rong L: miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep. 39:1631–1639. 2018.PubMed/NCBI
36	Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF and Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 113:316–328. 2005. View Article : Google Scholar : PubMed/NCBI
37	Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabete M, Kanter L, Lewensohn R and Dricu A: Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors. 25:1–8. 2007. View Article : Google Scholar : PubMed/NCBI
38	Xu F, Zhang YJ, Li L, Zhang YJ, Han JC, Yu YY and Ma CN: MicroRNA-214 inhibits the proliferation of non-small cell lung cancer via the suppression of IRS1. Int J Clin Exp Pathol. 9:22–29. 2016.